Background: Long-term topical treatment is often required for atopic dermatitis (AD), a chronic inflammatory skin disease.
Atopic dermatitis (AD), a chronic inflammatory skin disease characterized by eczematous lesions, an impaired epidermal barrier, and intense pruritus, is estimated to affect 15%-30% of children and 2%-10% of adults in industrialized countries. 1, 2 Given the chronic and recurrent nature of AD, long-term treatment is often necessary. [1] [2] [3] The American Academy of Dermatology; American Academy of Allergy, Asthma, and Immunology; and American College of Allergy, Asthma, and Immunology treatment guidelines for AD recommend topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI). 3, 4 Despite the favorable efficacy of TCS, AD treatment guidelines recommend limiting long-term use of high-dose TCS and restricting application sites to avoid cutaneous adverse events (AEs) (eg, atrophy, telangiectasia) and side effects associated with systemic absorption (eg, hypothalamic-pituitary axis suppression). [3] [4] [5] TCI are approved in the United States for short-term and noncontinuous long-term treatment, 3, 4 but a boxed warning is included for the potential for lymphoma or other malignancies with long-term use, 3, 4, 6, 7 despite recent reports refuting an increased risk for malignancy. [8] [9] [10] [11] No new topical treatments have been approved in the United States in [15 years for the treatment of AD. A novel topical therapeutic agent with the ability to mitigate the signs and symptoms of AD with reduced safety concerns would be useful for long-term disease management.
Phosphodiesterase-4 (PDE4), an intracellular enzyme involved in proinflammatory cytokine production, has been identified as a novel therapeutic target to control the underlying inflammation associated with AD. [12] [13] [14] PDE4 is overactive in inflammatory cells of patients with AD, leading to degradation of cyclic adenosine monophosphate and subsequent production of proinflammatory cytokines. [15] [16] [17] [18] Crisaborole ointment, 2% (Pfizer Inc, New York, NY), a treatment for mild to moderate AD, inhibits PDE4-dependent cyclic adenosine monophosphate degradation, which regulates nuclear factor kappa B and nuclear factor of activated T-cell signaling pathways to enhance the cellular control of inflammation. 13, 14, 19, 20 Results of preclinical studies have shown that crisaborole effectively penetrates the skin to inhibit cytokine release at the site of inflamed skin and is noncarcinogenic. [21] [22] [23] [24] In addition, crisaborole is rapidly and substantially metabolized to its inactive metabolites, thus limiting systemic exposure of the patient to active PDE4 inhibition and potential off-target side effects. 25 Phase 1 and phase 2 trials have demonstrated a favorable safety profile for crisaborole ointment and improvement in global and lesional disease severity. [25] [26] [27] [28] Two identically designed, 28-day, vehicle-controlled, pivotal phase 3 studies demonstrated that crisaborole ointment significantly improved global disease severity and all measured signs and symptoms of AD in patients $2 years of age with mild to moderate AD. 29 In addition, 28-day treatment with crisaborole ointment did not result in any serious treatment-related AEs, and most AEs were mild to moderate and were considered unrelated to treatment. 29 To assess the long-term safety of crisaborole ointment, crisaborole-and vehicle-treated patients from the phase 3 trials were enrolled in an open-label, single-arm, 48-week extension study (AD-303). The extent of drug exposure, AEs, and use of rescue therapy were assessed in children, adolescents, and adults with mild to moderate AD.
METHODS Study design and oversight
A multicenter, open-label, long-term safety study was conducted in the United States over 48 weeks in patients with mild to moderate AD after they completed a 28-day phase 3 pivotal study (AD-301, NCT02118766; AD-302, NCT02118792) (Fig 1) . Institutional review board approval was obtained for the protocol, informed consent/assent forms, and all relevant supporting data. The study was designed, conducted, recorded, and reported in compliance with the principles of Good Clinical Practice and all country-specific regulatory requirements. In accordance with the International Council on Harmonization technical requirements for the registration of pharmaceuticals for human use guidelines for the assessment of clinical safety for long-term treatment, the enrolled patient population size was large enough to ensure that a minimum of 100 and 300 patients completed 12 and 6 months of follow-up, respectively. 30 
CAPSULE SUMMARY d
Current topical treatments for atopic dermatitis are associated with long-term treatment safety concerns. A 48-week phase 3 safety study with crisaborole ointment, a nonsteroidal, anti-inflammatory, phosphodiesterase-4 inhibitor, demonstrated a low frequency of treatment-related adverse events.
Patients
Patients eligible for AD-303 must have completed the pivotal study (AD-301, AD-302) without experiencing a crisaborole treatment-related AE or a serious AE (SAE) that precluded further treatment with crisaborole ointment; they could enroll in the extension study within 8 days of day 36 of the pivotal studies. Key inclusion criteria required that patients be $2 years of age, have a clinical diagnosis of AD according to Hanifin and Rajka criteria, 31 and meet the eligibility criteria of AD-301 or AD-302, including a baseline Investigator's Static Global Assessment (ISGA) score of mild (2) or moderate (3). Key exclusion criteria included significant active infection or anticipated concomitant use of topical or systemic therapies that might alter the course of AD. Simultaneous use of TCS or TCI was prohibited throughout the study. Enrolled patients were categorized as children (2-11 years), adolescents (12-17 years), or adults ($18 years).
Crisaborole ointment treatment
Every 4 weeks (28 days), patient global disease severity was assessed using the ISGA, a 5-point scale from clear (0) to severe (4) (Fig 1) . If the patient's ISGA score was more than mild ($2) at evaluation, an on-treatment period with crisaborole ointment was initiated; if the ISGA was clear (0) or almost clear (1) , an off-treatment period was initiated. During on-treatment periods, patients were instructed to apply crisaborole ointment twice daily for 28 days to all treatable AD-involved areas, excluding the scalp because of the potential cosmetic incompatibility of ointment application on hair. Treatment with crisaborole ointment was discontinued if no improvement in ISGA score was observed after 3 consecutive on-treatment periods.
Assessments
On the first day of each 28-day cycle and on the final day of the study, disease severity (ISGA), concomitant medication use, vital signs, AEs, and SAEs were assessed in all patients. Primary end points were AEs, SAEs, and rescue therapy use. All AEs were based on investigator assessment and were recorded and classified by using the Medical Dictionary for Regulatory Activities. Based on investigator assessment, AEs were designated treatment related if they were definitely, possibly, or probably related to crisaborole treatment. Possibly or probably related AEs followed a reasonable temporal sequence and known or expected response pattern but could not have been reasonably explained by the patient's clinical state for possibly related AEs; probably related AEs could have been caused by a number of other factors.
At the discretion of the investigator, rescue therapy was prescribed and recorded. Rescue therapy was defined as the need for concomitant, nonconcurrent use of low-to mid-potency TCS or TCI. Analysis included the percentage of patients requiring rescue therapy days before TCS or TCI initiation and patient ISGA score before initiation.
Statistical analysis
Analysis of safety across age groups was assessed throughout the pivotal studies (4 weeks) and long-term safety study (48 weeks) for a total of 52 weeks. Longitudinal safety analyses from AD-303 only was separated into four 12-week periods. Inclusion criteria for analysis in each 12-week period was defined as reporting an AE during the period, AE resolution after the 12-week period, or a study visit or study completion visit after the 12-week period. The safety population included all patients who applied $1 confirmed dose of the study drug and had $1 postbaseline assessment. Descriptive statistics were used for all analyses.
RESULTS

Patients and enrollment
The safety population included all enrolled patients and was composed of a diverse population of 517 patients, including a strong representation of children (59.6%) and black or African American persons (29.4%) ( Table I) , reflective of the real-world patient population. 1, 2, 32, 33 For the pivotal studies, the mean percentage of treatable body surface area at baseline was similar between treatment groups and studies (crisaborole vs vehicle: AD-301, 18.8% vs 18.6%; AD-302, 17.9% vs 17.7%). 29 Crisaborole-treated patients from the pivotal studies made up 69.1% of the enrolled patient population, reflective of the 2:1 randomization to crisaborole and vehicle treatment. With the pivotal studies designated as the first on-treatment period, the study was considered complete when 271 patients (52.4%) had finished approximately 1 year and 396 patients had finished 6 months of safety follow-up in accordance with International Council on Harmonization guidelines for investigational drugs for long-term treatment. 30 The most frequent reasons for early study discontinuation were study closure (21.1%) and withdrawal by parent or guardian (12.2%) (Supplemental Table I ; available at http:// www.jaad.org).
Treatment exposure
The study population underwent an average of 6.2 on-treatment periods, including the pivotal trial. The extent of treatment exposure was similar across age groups; mean numbers of applications were 349.0 for patients 2-11 years of age, 349.4 for patients 12-17 years of age, and 347.7 for patients $18 years of age (Table I ). The mean amount of drug applied per application was 2.40 g, 2.29 g, and 2.10 g per respective age group, with a total population mean of 2.34 g. The mean duration of each on-treatment period was consistent across age groups; the total population on-treatment period mean was 28.4 days. During the extension study, most patients experienced $2 consecutive on-treatment periods during weeks 1-12 (68.5%) and $1 on-treatment periods during the remainder of the study (weeks 13-24, 74.3%; weeks 25-36, 67.3%; weeks 37-48, 68.2%). The mean amount of crisaborole ointment applied per patient per month was approximately 133 g.
Adverse events
The most commonly reported treatmentemergent adverse events (TEAEs) from the pivotal and long-term safety studies were upper respiratory tract infection (10.3%) and dermatitis atopic (11.2%) ( Table II) . Events coded as dermatitis atopic involved worsening, exacerbation, flare, or flare-up of an existing condition. Most TEAEs were mild (51.2%) or moderate (44.6%), did not differ among treatment periods, and were deemed unrelated to crisaborole treatment (93.1%). Seven treatment-emergent SAEs occurred in the long-term study and 2 occurred in the pivotal studies, but none were considered related to treatment.
Analysis of TEAEs over time in the long-term safety study was broken into four 12-week treatment periods to monitor the accumulation of side effects. The frequency of reported AEs was similar across all four 12-week treatment periods (Supplemental Table II ; available at http://www.jaad.org). The occurrence of diarrhea and vomiting, side effects that have been observed with oral PDE4 inhibitors, was low (Supplemental Table III ; available at http:// www.jaad.org). 34, 35 No safety signals were identified from vital signs or laboratory assessments, and the occurrence of neoplasms or infections did not increase with long-term treatment.
Treatment-related adverse events
In the pivotal and long-term extension studies, treatment-related AEs occurred in 10.3% of patients, and most (85.9%) were mild or moderate. The most frequently reported treatment-related AEs were dermatitis atopic (worsening, exacerbation, flare, or flare-up) (n = 16; 3.1%), application-site pain (burning or stinging) (n = 12; 2.3%), and application-site infection (n = 6; 1.2%) (Fig 2) . Median duration (range) for each of the most frequently reported treatment-related AEs was 17.5 (11-33) days, 5.0 (1-30) days, and 12.0 (9-197) days for dermatitis atopic, application-site pain, and application-site infection, respectively. The percentage of treatment-related application-site pain AEs that resolved within a day was 33.3% Extent of exposure summarizes exposure to crisaborole ointment from AD-301, AD-302, and AD-303. SD, Standard deviation. *Amount of drug used was set to 0 for patients who were not dispensed crisaborole ointment and for patients with no complete dispense and return weight records.
(n = 4). Most dermatitis atopic events (n = 9; 90.0%) and application-site infections (n = 3; 75.0%) resolved within 1 treatment period. Only half the application-site pain events occurred during the long-term extension study (n = 6; 1.2%). The frequency of treatment-related AEs during the long-term study did not increase over time (Supplemental Fig 1; available at http://www.jaad. org). In addition, there was no evidence of application-site cutaneous adverse reactions, such as atrophy or telangiectasia, side effects that have been reported with long-term TCS treatment.
3,36
Rescue therapy use Most patients (77.8%) did not require rescue therapy throughout the long-term study. For those patients who did require rescue therapy, an average of 150 treatment days preceded rescue therapy use, and most (83.1%) were initiated because of AD (ISGA scores of mild/2 or moderate/3). The mean number of days on rescue therapy was 21.4 and 24.2 for TCS (n = 155) and TCI (n = 6), respectively. Rescue therapy was observed in 22.4% of children, 26.0% of adolescents, and 12.7% of adults. Most patients (79.1%) resumed crisaborole ointment treatment at a later date, and 75.7% remained in the study until week 48 or study closure. The mean number of days before return to crisaborole ointment was 14.4 days and 25.7 days for TCS and TCI rescue therapy, respectively.
DISCUSSION
The safety profile of crisaborole ointment was favorable overall for long-term treatment of patients $2 years of age with mild to moderate AD. The study design allowed for a comprehensive analysis of the safety of crisaborole through the significant amount of crisaborole ointment used (;133 g/patient/month of treatment). A positive safety profile for crisaborole was demonstrated by a low frequency of TEAEs; a low frequency of treatment-related AEs, most of which were mild to moderate; no accumulation of AEs over time; and minimal need for rescue therapy by patients. These results demonstrate that crisaborole ointment may be a potential option for long-term treatment of AD, an important benefit of a topical therapeutic given the chronic nature of AD.
The design of the current study and the enrolled patient population are relevant for the treatment paradigms and populations in the real world. On-treatment and off-treatment periods allowed for crisaborole ointment application to AD flares, providing context for crisaborole use as maintenance therapy. Furthermore, 59.6% of the patients in the current study were children, which is representative of the global patient population in which ;85% of patients develop symptoms by 5 years of age. 37 In addition, 29.4% of the patients (n = 152) were black, providing rich information on a patient population that is often underrepresented in AD clinical trials 33, 38 despite indications that AD is more prevalent in black children than in white children (15.9% vs 9.7%). 32 Across the 52 weeks of safety analysis of the pivotal and long-term treatment study, most treatment-related AEs were mild to moderate. During the 4-week pivotal studies, application-site pain, reported in 4.4% (n = 45) of crisaborole-treated patients, resolved in most patients within 1 day. 29 A lower incidence of application-site pain was observed among the patients who participated in the long-term treatment study (n = 12; 2.3%), and the incidence decreased with time. Half the reactions occurred during the pivotal trials (n = 6; 1.2%), and most of the other reactions occurred within the first 3 months of the extension study (n = 5; 1%). A low incidence of dermatitis atopic (n = 16; 3.1%) and application-site infection (n = 6; 1.2%) was observed in the patients enrolled in the pivotal studies and the extension study; most resolved within 1 month. These data indicate that crisaborole could be applied as maintenance therapy without unwanted side effects. Concerns about long-term use of TCS are associated with systemic and cutaneous side effects, which are observed as early as 4 weeks after the start of therapy. [39] [40] [41] In this long-term safety study, crisaborole was used predominantly as monotherapy and did not result in cutaneous side effects. In addition, most patients who required rescue therapy generally used it for \1 month and returned to crisaborole treatment after its use. These data indicate that intermittent TCS or TCI use did not affect the safety profile of crisaborole ointment, but future studies would be needed to analyze the safety of concomitant TCS or TCI use with crisaborole ointment.
Future studies powered to analyze the long-term effectiveness of crisaborole will further the understanding of the role crisaborole could play in the long-term treatment of AD and in addressing the chronic nature of AD. Pivotal phase 3 studies demonstrated early relief of the signs and symptoms of AD with crisaborole treatment, 29 and this current phase 3 extension study demonstrated few safety concerns, indicating that crisaborole has the potential to treat AD over an extended period of time without the safety profile of current therapies. Overall, crisaborole ointment represents a novel alternative to current pharmacologic topical therapies for the early relief and management of AD. J AM ACAD DERMATOL VOLUME 77, NUMBER 4 Supplemental Supplemental Table III . Treatment-emergent adverse events reported by $1% of patients of long-term safety study (safety population) by 12-week period 
